CClinicalTrials.gg
CompletedNCT03156725Updated May 17, 2017

Assessment of Iron Absorption From Aspergillus Oryzae

An interventional study of Ferrous Sulfate and Aspiron in Iron Bioavailability, sponsored by Iowa State University. Completed. Open to female participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-05-17.

Sponsored by Iowa State University · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Registered 2 years 11 months after the study started (first participant enrolled May 2014, registered May 2017).
Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
Female
01

Study summary

The objective of this study was to compare the absorption of a new iron product, iron enriched Aspergillus oryzae to ferrous sulfate in humans using a double stable-isotope technique.

Read the detailed description

Iron deficiency anemia (IDA) remains a health crisis worldwide, especially among productive age women and children. Primarily, inorganic iron salts are being used as iron supplementation to treat IDA and are added to food to improve the nutritional value of the daily diet, however side effects and/or low absorption with diets are a result, limiting the impact on IDA. Sixteen female subject, who were 18-35 years, non-pregnancy, non-anemia with marginal lower iron status (ferritin cut-off value \<30ug/L) were recruited in this study. Subjects were randomized to orally consume test meal with stable iron isotopes Fe57 (10mg) in sulfate form and Fe58 (2mg) and 8 mg natural abundance iron in Aspiron, in two visits. Blood samples were collected at baseline and two weeks to assess isotope enrichment and iron status indicators, such as hepcidin and ferritin were measured.

02

Conditions studied

  • Iron Bioavailability

Keywords

  • Iron Bioavailability
  • hepcidin
  • ferritin
  • iron absorption
  • iron status
03

In context

Lead sponsor

Iowa State University is the lead sponsor of 36 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Marginal iron status (Serum ferritin \<30ug/L)
  • BMI in the range 18.5-24.9 kg/m2
  • Willing to discontinue vitamin and mineral supplements 2 weeks prior and during the study
  • Willing to consume stable iron isotope labelled supplement
  • Willing to stop getting blood drawn 2 weeks prior to the study and during the study
  • Willing to give multiple blood samples at beginning and end of study

Exclusion criteria

Exclusion Criteria:

  • Pregnant
  • Lactating
  • Smoker
  • Anemic (hemoglobin \< 120 g/L)
  • Has gastro-intestinal disease/condition that can affect absorption
  • Allergic to any of the meal components
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Single group
Masking
Single (Participant)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Ferrous Sulfate

    The ferrous sulfate group was required to consume a test containing ferrous sulfate (10 mg of 57Fe). Participants received a meal containing 17.6 g egg albumin, 45 g corn syrup solids, 17.5 g corn oil, 6 ml vanilla extract, and 100 ml of distilled water.

    Drug: Ferrous Sulfate

  • Experimental
    Aspiron

    The Asprion group was required to follow the same protocol as the 57Fe experimental group, with the exception of taking A. Oryzae containing (8 mg natural abundace Fe and 2 mg 58Fe. Meals composition was similar to ferrous sulafte group.

    Dietary Supplement: Aspiron

Interventions

  • DrugFerrous Sulfate
  • Dietary supplementAspiron
06

What researchers measure

Primary outcomes

  1. iron absorption

    Isotope enrichment in the blood samples

    Time frame: 15 days

Secondary outcomes

  1. iron status

    hepcidin and ferritin

    Time frame: 15 days

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No — Publication in a journal

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 17, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03156725
Lead sponsor
Iowa State University
Responsible party
Dr. Manju B. Reddy (Professor, Iowa State University) — Principal investigator
First posted
May 17, 2017
Start date
May 19, 2014
Primary completion
Sep 14, 2014
Completion
Jun 4, 2016
Last update
May 17, 2017

Study contacts

Manju B Reddy, PhD
principal investigator · Iowa State University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion